Peter Fernandes

Peter Fernandes discloses dealings in Bellerophon Therapeutics, Inc. to SEC (Form 4). We count 2 filings; the first trade dates from 19 January 2016 and the latest from 9 December 2022.

None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.

Most recently, on 13 December 2022, the filings show an option exercise in Bellerophon Therapeutics, Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.